Abstract
During the last few years a novel role for previously known Zn(II) aminopeptidases has emerged, attracting a great deal of scientific interest to these molecules. Aminopeptidases appear now to play a key role in the last, yet crucial, proteolytic steps that generate small peptides for presentation onto MHC class I molecules so that the mature MHCpeptide complexes can be recognized by cytotoxic T-lymphocytes. In that context, ER aminopeptidases have been shown to strongly affect the adaptive immune response. ER aminopeptidase 1 (ERAP1) has been demonstrated to be a critical determinant of the immune response by generating mature antigenic epitopes from peptide precursors that arrive into the ER originating primarily from intracellular proteins degraded by the proteasome. At least one more related aminopeptidase, renamed ERAP2, appears to have important yet distinct roles in antigenic peptide generation. This review discusses recent findings that help to unravel the role of ER aminopeptidases in the immune response as well as the molecular properties that underlie this role. Determining the exact role and mechanism of action of these aminopeptidases will potentially provide tools for the pharmaceutical manipulation of the immune response on a subtle and qualitative level leading to novel therapeutic opportunities for the treatments of diseases ranging from autoimmunity to cancer.
Current Pharmaceutical Design
Title: A New Role for Zn(II) Aminopeptidases: Antigenic Peptide Generation and Destruction
Volume: 15 Issue: 31
Author(s): Irini Evnouchidou, Athanasios Papakyriakou and Efstratios Stratikos
Affiliation:
Abstract: During the last few years a novel role for previously known Zn(II) aminopeptidases has emerged, attracting a great deal of scientific interest to these molecules. Aminopeptidases appear now to play a key role in the last, yet crucial, proteolytic steps that generate small peptides for presentation onto MHC class I molecules so that the mature MHCpeptide complexes can be recognized by cytotoxic T-lymphocytes. In that context, ER aminopeptidases have been shown to strongly affect the adaptive immune response. ER aminopeptidase 1 (ERAP1) has been demonstrated to be a critical determinant of the immune response by generating mature antigenic epitopes from peptide precursors that arrive into the ER originating primarily from intracellular proteins degraded by the proteasome. At least one more related aminopeptidase, renamed ERAP2, appears to have important yet distinct roles in antigenic peptide generation. This review discusses recent findings that help to unravel the role of ER aminopeptidases in the immune response as well as the molecular properties that underlie this role. Determining the exact role and mechanism of action of these aminopeptidases will potentially provide tools for the pharmaceutical manipulation of the immune response on a subtle and qualitative level leading to novel therapeutic opportunities for the treatments of diseases ranging from autoimmunity to cancer.
Export Options
About this article
Cite this article as:
Evnouchidou Irini, Papakyriakou Athanasios and Stratikos Efstratios, A New Role for Zn(II) Aminopeptidases: Antigenic Peptide Generation and Destruction, Current Pharmaceutical Design 2009; 15 (31) . https://dx.doi.org/10.2174/138161209789271816
DOI https://dx.doi.org/10.2174/138161209789271816 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Health Benefits of Buckwheat (Fagopyrum Esculentum), Potential Remedy for Diseases, Rare to Cancer: A Mini Review
Infectious Disorders - Drug Targets Hepatic Effects of Duloxetine – III: Analysis of Hepatic Events Using External Data Sources
Current Drug Safety Green Tea from the Far East to the Drug Store: Focus on the Beneficial Cardiovascular Effects
Current Pharmaceutical Design Imaging of Organ Metabolism in Obesity and Diabetes: Treatment Perspectives
Current Pharmaceutical Design Pharmacokinetic Study of Amlodipine in Human Urine Using On-Line Coupled Isotachophoresis-Capillary Zone Electrophoresis with Diode Array Detection
Current Pharmaceutical Analysis Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology Regulation of Adrenomedullin and its Family Peptide by RAMP System – Lessons from Genetically Engineered Mice
Current Protein & Peptide Science Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions
Current Drug Metabolism Optical Imaging of Microvascular Morphology and Perfusion
Current Angiogenesis (Discontinued) Anti-Platelet Treatment of Middle-Sized Abdominal Aortic Aneurysms
Current Vascular Pharmacology Preeclampsia Prediction in Type 1 Diabetes and Diurnal Blood Pressure Methodology
Current Hypertension Reviews Chronic Inflammatory Diseases and the Acute Respiratory Distress Syndrome (ARDS)
Current Pharmaceutical Design Current Update in the Management of Diabetic Nephropathy
Current Diabetes Reviews Withdrawal Notice: Mucoadhesive Microspheres: An Emerging Trends in Therapy of Diabetes Mellitus
Current Diabetes Reviews From Cerebrospinal Fluid Pulsation to Noninvasive Intracranial Compliance and Pressure Measured by MRI Flow Studies
Current Medical Imaging Is There a Role for PDE5 Inhibitors in the Management of Male Infertility Due to Defects in Testicular or Epididymal Function?
Current Pharmaceutical Design Interleukin-6 and Lung Inflammation: Evidence for a Causative Role in Inducing Respiratory System Resistance Increments
Inflammation & Allergy - Drug Targets (Discontinued) Bioorganic Compounds Produced by the Fungus Monascus and their Use in Health Sciences and Medicine
Mini-Reviews in Organic Chemistry Update on the Medical Treatment of Allergic Rhinitis
Inflammation & Allergy - Drug Targets (Discontinued) Chronic Inflammatory Disorders and Accelerated Atherosclerosis: Chronic Kidney Disease
Current Pharmaceutical Design